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Objective: The objective of this study was to evaluate the results of prosthetic carotid bypass (PCB) with polytetra-
fluoroethylene (PTFE) grafts as an alternative to carotid endarterectomy (CEA) in treatment of restenosis after CEA or
carotid artery stenting (CAS).
Methods: From January 2000 to December 2014, 66 patients (57 men and 9 women; mean age, 71 years) presenting with
recurrent carotid artery stenosis $70% (North American Symptomatic Carotid Endarterectomy Trial [NASCET] criteria)
were enrolled in a prospective study in three centers. The study was approved by an Institutional Review Board. Informed
consent was obtained from all patients. During the same period, a total of 4321 CEAs were completed in the three
centers. In these 66 patients, the primary treatment of the initial carotid artery stenosis was CEA in 57 patients (86%) and
CAS in nine patients (14%). The median delay between primary and redo revascularization was 32 months. Carotid
restenosis was symptomatic in 38 patients (58%) with transient ischemic attack (n ¼ 20) or stroke (n ¼ 18). In this series, all
patients received statins; 28 patients (42%) received dual antiplatelet therapy, and 38 patients (58%) received single
antiplatelet therapy. All PCBs were performed under general anesthesia. No shunt was used in this series. Nasal intu-
bation to improve distal control of the internal carotid artery was performed in 33 patients (50%), including those with
intrastent restenosis. A PTFE graft of 6 or 7 mm in diameter was used in 6 and 60 patients, respectively. Distal anastomosis
was end to end in 22 patients and end to side with a clip distal to the atherosclerotic lesions in 44 patients. Completion
angiography was performed in all cases. The patients were discharged under statin and antiplatelet treatment. After
discharge, all of the patients underwent clinical and Doppler ultrasound follow-up every 6 months. Median length of
follow-up was 5 years.
Results:No patient died, sustained a stroke, or presented with a cervical hematoma during the postoperative period. One
transient facial nerve palsy and two transient recurrent nerve palsies occurred. Two late strokes in relation to two PCB
occlusions occurred at 2 years and 4 years; no other graft stenosis or infection was observed. At 5 years, overall actuarial
survival was 81% 6 7%, and the actuarial stroke-free rate was 93% 6 2%. There were no fatal strokes.
Conclusions: PCB with PTFE grafts is a safe and durable alternative to CEA in patients with carotid restenosis after CEA or
CAS in situations in which CEA is deemed either hazardous or inadvisable. (J Vasc Surg 2017;-:1-9.)The incidence of significant recurrent carotid artery ste-
nosis $70% after primary carotid endarterectomy (CEA)
and after carotid artery stenting (CAS) varies from 0.6%
to 15%.1-4 Restenosis may result from intimal hyperplasia,
usually within 24 months of the primary operation, or
from recurrent atherosclerosis beyond this time interval.5
Symptoms of cerebral ischemia are present in up to 5%
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x.doi.org/10.1016/j.jvs.2016.11.046symptomatic and severe degree of restenosis >70%.3 Re-
ports on redo CEA have shown that its results are essen-
tially comparable to those of primary CEA.8,9
Nonetheless, scar tissue dissection in redo CEA may
expose patients to a risk of cranial nerve injuries.3 CAS
has been proposed as an alternative to repeated CEA,
in view of reducing the morbidity associated with itera-
tive surgery in a scarred field. However, the incidence of
in-stent restenosis after CAS as a repeated procedure is
significant, reaching 13.5% at 5 years,1,10,11 with a 4-year
patency rate of 76%.12 For these reasons, we wish to sug-
gest that carotid bypass could be a viable alternative to
both repeated CEA and CAS. This prospective study eval-
uated the results of prosthetic carotid bypass (PCB) with
polytetrafluoroethylene (PTFE) grafts in treatment of
restenosis after CEA or CAS in situations for which
repeated CEA is deemed inadvisable.
METHODS
From January 2000 to December 2015, 99 patients (83
men and 16 women; mean age, 72 years) were admitted1
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--- 2017for treatment of $70% recurrent carotid artery stenosis
(North American Symptomatic Carotid Endarterectomy
Trial [NASCET] criteria) and enrolled in a prospective
study at two academic hospitals and one affiliated cen-
ter. This figure represents 2.3% of the 4321 open carotid
artery revascularizations performed by the same authors
during the same time. In this study, all 99 patients
received open surgical revascularization for treatment
of the restenosis. At operation, transmural or inflamma-
tory carotid lesions with dense scarring, no plane for end-
arterectomy, distal extension beyond C2, and restenoses
after CAS were treated with carotid bypass, whereas
more limited lesions on a carotid wall that would tolerate
a repeated endarterectomy with a safe cleavage plane
were treated with repeated CEA. The study was
approved by the Institutional Review Board, and
informed consent for repeated carotid artery revascular-
ization was obtained from all the patients. The 66 pa-
tients (57 men and 9 women; mean age, 71 years) who
underwent carotid bypass are the subject of this study;
the remaining 33 patients received repeated CEA (Fig 1).
The 66 bypasses for repeated revascularization represent
30% of 221 carotid artery bypass procedures performed
by the authors for atherosclerotic disease during the
same period. Thirty-eight patients (58%) presented with
neurologic symptoms, including transient ischemic at-
tacks in 20 cases and minor stroke in 18 cases.
Demography and patient risk factors are reported in
Table I. Primary treatment of the initial carotid artery ste-
nosis was CEA in 57 patients (80%) and CAS in 9 patients
(14%). The median interval between primary and second-
ary revascularization was 32 months (18-84 months).
Primary, open revascularization consisted of standard
CEA with primary closure in 27 cases (47%), patch closure
in 25 cases (44%), and eversion CEA in 5 cases (9%).
Recurrent carotid stenosis was diagnosed at duplex ul-
trasound (DUS), showing a peak systolic velocity (PSV)
>250 cm/s, and confirmed at computed tomography
(CT) scan or magnetic resonance imaging by NASCET
criteria. In this series, repeated carotid revascularization
in asymptomatic patients was carried out in case of
worsening of the carotid restenosis on DUS between
two time points, reaching a PSV above 350 cm/s.
At the time of reoperation, all patients received statins
and antiplatelet treatment. Thirty-eight patients (58%)
received oral aspirin alone (160 mg/d), whereas 28 pa-
tients (42%) received aspirin and clopidogrel (75 mg/d)
because of a recent (<6 months) percutaneous coronary
intervention with drug-eluting stents. Dual antiplatelet
therapy was stopped on the day of operation and
resumed on the first postoperative day. Intraoperatively,
5000 IU of sodium heparin was administered before arte-
rial clamping, and it was not blocked at the end of the
intervention. Subcutaneous enoxaparin (2000 IU every
12 hours) was administered, starting 6 hours after the
operation and stopped on discharge. Enoxaparin wasadministered to all the patients, regardless of their peri-
operative antiplatelet treatment, either single or dual.
Antibiotic prophylaxis was performed as a single intrave-
nous injection of a bolus of cephalosporin before skin inci-
sion. All of the operations were performed under general
anesthesia. The status of cerebral perfusion during clamp-
ing was assessed by internal carotid artery backbleeding
and transcutaneous oximetry (INVOS; Covidien-
Medtronic, Fridley, Minn) and remained satisfactory in all
patients. No shunt was used in this series. Median carotid
clamping time was 21 minutes (17-34 minutes).
In patients with high carotid bifurcation or a stenosis
extending beyond the level of C2 on preoperative CT
scan (n ¼ 33), the difficulty of obtaining distal internal ca-
rotid artery control was anticipated and surmounted in
all cases by nasal intubation and section of the digastric
muscle. To avoid intense scarring surrounding the ca-
rotid bifurcation, retrojugular dissection was carried out
in 36 patients (54%; Fig 2). The graft material consisted
of a nonringed PTFE graft of 7 mm in diameter in 60 pa-
tients and 6 mm in diameter in six patients (W. L. Gore &
Associates, Flagstaff, Ariz). The distal anastomosis was
constructed end to side in 44 patients, with a clip distal
to the atherosclerotic lesion, and end to end in 22 pa-
tients (Fig 3). The proximal anastomosis was lateral to
the common carotid artery in all cases. Completion angi-
ography was performed in all patients, showing a spasm
of the distal internal carotid artery in three cases, which
was eliminated with local use of papaverine (Fig 4). Pre-
operative and postoperative neurologic status of all pa-
tients with repeated carotid surgery was assessed by a
neurologist providing an independent evaluation for
any hemispheric deficit and postoperative cranial nerve
palsy. Arterial reconstruction patency was assessed by
DUS and magnetic resonance angiography or CT scan
(Fig 5) at discharge, followed by DUS every 6 months.
The patients were discharged under statins and single
or dual antiplatelet therapy according to their preopera-
tive treatment status.
Follow-up. Median length of follow-up was
63.4 months (1-132 months). Primary end points were
postoperative stroke or death and cranial nerve injury;
secondary end points were occurrence of a cervical
Fig 1. Cohort selection of patients for repeated carotid revascularization. CAS, Carotid angioplasty and stenting;
CEA, carotid endarterectomy; PTFE, polytetrafluoroethylene.
Table I. Demography and risk factors
Baseline characteristics No. (%)
Mean age, years (range) 71 (62-83)
Male gender 57 (86)
Hypertension 53 (81)
Current smokers 52 (79)
Hyperlipidemia 44 (67)
Coronary artery disease 31 (47)
Diabetes 17 (26)
Lower limb occlusive arterial disease 3 (4)
Chronic renal insufficiency 2 (3)
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or graft occlusion. Postoperative stroke or death was
defined as any stroke or death occurring within 30 days
after the operation or during the hospital stay. Hema-
toma was defined as any condition requiring reoperation
for hemostasis. Cranial nerve injury was defined as any
postoperative cranial nerve palsy. Graft infection was
defined as any clinical situation requiring PTFE graft
excision, followed by replacement with an autologous
arterial substitute or arterial ligation or any clinical or CT
scan evidence of graft infection. Late stroke was defined
as any new ipsilateral ischemic stroke occurring after
discharge from the hospital and during the whole lengthof follow-up. Late de novo restenosis was defined as any
restenosis >70%, associated with a PSV >250 cm/s
measured on DUS and confirmed by CT scan or mag-
netic resonance imaging by the NASCET criteria.
Life-table analysis according to the Kaplan-Meier
method was used to calculate late survival and freedom
from late stroke and restenosis.
RESULTS
The 66 patients in this series were operated on during a
16-year-period by the three senior surgeons (G.I., F.G.C.,
J.B.R.). Median length of stay was 3 days (2-8 days). It
was significantly longer in the early period of the study
and shorter in the later years. Currently, median length
of stay for open repeated carotid revascularization is
48 hours, comparable to standard primary CEA. Seven
of these patients had already received irradiation 10 to
20 years before index CEA.
No patient died, sustained a stroke, or presented with a
cervical hematoma during the postoperative period. Two
transitory recurrent nerve palsies and one transitory facial
nerve palsywere observed. They accounted for 4.5%of the
whole series and had completely revertedwithin 2 weeks.
No postoperative death, stroke, or cranial nerve injury was
observed in the repeated CEA group of patients.
Two late strokes (3%) associated with two carotid
bypass occlusions (3%) occurred at 2 years and 4 years
postoperatively. In these cases, DUS performed,
Fig 2. Retrojugular approach to the common and the
distal internal carotid artery for repeated carotid surgery.
This approach was preferred in case of dense scarring
involving the carotid bifurcation and the internal jugular
vein.
Fig 3. Carotid bypass from the common carotid artery to
the internal carotid artery using a 7-mm-diameter poly-
tetrafluoroethylene (PTFE) graft.
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graft showed a normal flow pattern within the grafts. No
graft infection was observed.
At 5 years, the overall actuarial survival ratewas 81%6 7%
(Fig 6), with graft patency of 93%6 2% (Fig 7) and a stroke-
free rate of 93% 6 2% (Fig 8). There were no fatal strokes.DISCUSSION
The results of this study show that PTFE carotid bypass
is a viable alternative to CEA in treatment of severe,
recurrent carotid stenosis after CEA or CAS.
In this series, 38 patients (58%) with 50% to 99%
carotid restenosis presented with ipsilateral carotid
territory symptoms and underwent repeated carotid
revascularization as recommended by Rothwell et al.13
Other patients presented >70% asymptomatic resteno-
sis. Despite the intuitive belief that most asymptomatic
restenoses are benign, this is not necessarily the case in
current practice, and a recent meta-analysis suggested
that two-thirds of the patients undergoing interventionsfor carotid restenosis were asymptomatic.14 Further-
more, in the Asymptomatic Carotid Surgery Trial
(ACST),15 13% of the patients with carotid restenosis
who progressed to occlusion suffered a stroke when it
occurred, and an additional 10% suffered an ipsilateral
stroke at a later time. It therefore appears advisable to
repeat carotid revascularization in patients with severe
(>70%) carotid artery restenosis progressing to PSV
>350 cm/s. To date, no randomized controlled trial has
compared repeated surgery with CAS in treatment of
carotid restenosis. In a 2015 meta-analysis of 13 studies
in which repeated CEA was compared with CAS,14 there
was no difference in 30-day stroke/death (2.3% after CAS
vs 2.7% after repeated CEA). However, according to the
meta-analysis by Tu et al,1 overall incidence of restenosis
at 5 years after repeated CEA was 4.4% compared with
13.5% after CAS and 7% in our series after PCB. CAS for
carotid restenosis has also been reported in other series,
with an incidence of in-stent restenosis ranging from
3.6% at 2 years16 to 19% at 3 years.12,17 Better results of
CAS compared with open revascularization have
recently been reported by Dorigo et al18 and by Attigah
et al.19 However, in both series, CAS was performed
mainly in patients with an early carotid restenosis usu-
ally limited to intimal hyperplasia rather than in those
with more complex and extensive carotid lesions
treated by repeated CEA. Rate of freedom from any
stroke or restenosis was 93% at 5 years in our series
and 100% in a comparable series by Spinelli et al,3
showing that compared with CAS, PCB yields excellent
long-term patency.
When deciding on a repeated open surgical revascular-
ization after primary CEA or CAS, the surgeon has two
choices: either repeated CEA or bypass. Although there
has been no randomized trial addressing this issue, a
retrospective analysis of prospectively stored data by
Archie20 showed that repeated CEA with patch and
PTFE bypass grafts yielded comparable outcomes. How-
ever, there exist differences tending to favor carotid
bypass. The main issue with CEA for restenosis is that it
may be neither advisable nor possible in many patients
because of an inflammatory process involving the carotid
wall after CAS or a transmural atheromatous lesion in
late severe carotid artery restenosis after CEA. In these
situations, PCB is much more appropriate than repeated
CEA. It eliminates the need to perform endarterectomy
on an inflammatory carotid wall without a well-
delimited cleavage plane or on a carotid with a transmu-
ral atheromatous lesion. In these situations, a bypass with
proximal and distal anastomoses on a nondiseased
artery may be safer and compares favorably with other
series of repeated CEA.18,19 A summary of the outcomes
in recent series of CEA, CAS, or PCB for carotid restenosis
is given in Table II.
Taking into account thematerial used in carotid bypass,
the great saphenous vein (GSV) or a PTFE graft can be
Fig 5. Postoperative magnetic resonance angiography
showing the usual figure of a common to internal carotid
artery bypass with a distal end-to-end anastomosis.
Fig 4. Completion angiography showing spasm of the distal internal carotid artery (A), resolved after local
application of papaverine (B).
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yield excellent postoperative and long-term outcomes
when carried out as an elective alternative to CEA.21
Following the study by Spinelli et al,3 our series showedcomparable results when PTFE was used for repeated
carotid revascularization with freedom from stroke of
93% at 5 years, a finding in agreement with the previous
reports. Conversely, use of the GSV as a carotid substitute
has been associated with a high rate of restenosis,1,21,22
with cumulative freedom from occlusion or recurrent
stenosis >70% of 83% at 5 years23 compared with 93%
in our series.
According to Cormier et al23 and Berguer et al,24
use of a GSV has significant limitations; only segments
4 to 5 mm in diameter are usable, whereas
segments <4 mm in diameter or with a thick wall are
prone to restenosis or early thrombosis, and segments
>5 mm in diameter are prone to aneurysm. Another
drawback is that one prerequisite GSV feature is lack of
valves, which involves a potential risk of postoperative
embolism. An additional disadvantage of vein grafts
is that to obtain a segment of adequate diameter, it
is necessary to harvest the GSV at the thigh level,
which means potential thrombosis of the remaining
segment of the vein and consequently a high likelihood
that it will become unusable for future revascularization
procedures.
The last issue concerning the risk of repeated open sur-
gical revascularization for carotid restenosis compared
with CAS consists of the occurrence of cranial nerve
palsy. Its overall incidence after repeated CEA is
Fig 7. Kaplan-Meier estimate of prosthetic carotid bypass (PCB) patency at 5 years.
Fig 6. Kaplan-Meier estimate of overall survival rate at 5 years.
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of the cases.1,5,8,25,26 In this series, the incidence was 4.5%,
and it was transitory in all cases. Similar results have been
reported by others with PCB when it was used to treat
restenosis after primary CEA and CAS.3 An element that
may have contributed to the low incidence of transitory
cranial nerve palsy is the retrojugular approach used in
36 patients (56%) of this series, which allowed access to
the common and internal carotid arteries in zones free
from scarring.27 The frequent use of nasal intubation,
enabling enhanced control of the distal internal carotid
artery, may also have reduced the risk of cranial nerve
trauma.Regarding general complications, myocardial infarction
(MI), which is estimated to occur postoperatively in 1.3% of
open carotid revascularization,1 has been considered the
main drawback of repeated carotid surgery compared
with CAS.28 However, previous studies have reported no
postoperativeMIafter open treatmentof recurrent carotid
stenosis by either CEA or PCB,3,9 and other studies have
shown no significant difference in the incidence of MI
between open repeated revascularization and CAS.18,19,22
We did not observe any postoperative MI in our series of
66patients. Thismaybedue to ourpolicy of systematically
performing preoperative coronary angiography in all pa-
tients who are candidates for carotid revascularization
Table II. Outcome of carotid angioplasty and stenting (CAS), carotid endarterectomy (CEA), and carotid bypass for reste-
nosis after CEA
Author Year Procedures, No. 30-Day death, % 30-Day stroke, % Mean follow-up, years Rate of restenosis, %
CAS
Setacci16 2005 15 d d 1 0
De Borst12 2007 57 d 3.5 3 19
AbuRahma5 2010 120 d 1 2 4
Attigah19 2010 45 d 2.2 2.9 5
Brott28 2010 1262 0.7 4.1 4 NS
Midy17 2011 249 0.4 3.6 2.4 8.4
Dorigo18 2013 58 d d 2 6.5
Tu1 2015 2174 0.9 2.4 5 13.5
CEA
AbuRahma5 2010 72 d 3 2.75 3
Attigah19 2010 41 d 9.7 2.9 11
Brott28 2010 1240 0.3 2.3 4 NS
Coscas26 2010 119 0.8 1.7 5 6.7
Dorigo18 2013 37 d d 2 28.3
Tu1 2015 2392 1 2.8 5 4.4
Carotid bypass
Spinelli3 2014 21 d d 5.4 0
Present series 66 d d 5 3
NS, Not specified.
Fig 8. Kaplan-Meier estimate of stroke-free rate at 5 years.
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stenoses before carotid revascularization.29,30 Following a
recent percutaneous coronary intervention using drug-
eluting stents, we performed PCB under dual antiplatelet
treatment in 28 patients (42%) without any cervical
hematoma requiring surgical drainage.Finally, limitations of the study are twofold: first, the
time span, which extends during a 16-year-period;
and second, the lack of a control group treated
with CAS. Nonetheless, our data and outcomes were
objectively assessed, thereby rendering the results
reliable.
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PCB with PTFE grafts is a safe and durable alternative to
CEA in patients with carotid restenosis after CEA or CAS
in situations in which CEA is deemed either hazardous or
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